Categories Earnings, Health Care

Gilead Sciences tops Q1 earnings estimate, reiterates full-year outlook

Shares of Gilead Sciences (NASDAQ: GILD) gained 1.2% after the biotechnology firm reported first-quarter earnings of $1.76 per share, surpassing the street view of $1.64 per share. Revenues came in at $5.28 billion, up 3.8% year-over-year, narrowly topping analysts’ projection of $5.27 billion.

On a reported basis, net income was $2 billion or $1.54 per share compared to $1.5 billion or $1.17 per share in the previous year quarter.

Gilead Sciences Q1 2019 earnings results

HIV product sales jumped 12.5% to $3.6 billion, primarily driven by higher sales volume as a result of the continued uptake of Biktarvy. HCV product sales were $790 million vs. $1 billion for the same period in 2018. The decline was primarily due to lower patient starts and competitive dynamics, including a decline in price in US Medicare, in 2019.

Looking ahead into fiscal 2019, the company reiterated its product sales in the range of $21.3 billion to $21.8 billion and adjusted product gross margin in the range of 85% to 87%.

READ: IMMUNOGEN IS CHEAP AHEAD OF EARNINGS, BUT IS IT WORTH?

The first quarter earnings come a month after the California-based firm failed to meet the primary endpoint of its most advanced NASH (nonalcoholic steatohepatitis) candidate, selonsertib, in a Phase 3 trial.

Gilead stock has increased by just 2.5% in the year-to-date period, while its peer companies have achieved double-digit growths. The broader industry has, meanwhile, achieved a growth of about 17% during the same period.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

V Earnings: Key quarterly highlights from Visa’s Q1 2023 financial results

Visa Inc. (NYSE: V) reported first quarter 2023 earnings results today. Net revenues grew 12% year-over-year to $7.9 billion. GAAP net income rose 6% to $4.2 billion while EPS grew

Earnings: Highlights of Intel’s (INTC) Q4 2022 financial results

Intel Corporation (NASDAQ: INTC) Thursday reported a decline in adjusted earnings and revenues for the fourth quarter. The semiconductor giant also provided guidance for the first quarter of 2023. Fourth-quarter

McCormick (MKC) expects to drive sales growth in 2023 through pricing actions and cost savings

Shares of McCormick & Company Inc. (NYSE: MKC) were down over 5% on Thursday after the company missed expectations on its fourth quarter 2022 results and provided a lower-than-expected earnings

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top